605116 logo

Aurisco Pharmaceutical Co.,Ltd. Stock Price

SHSE:605116 Community·CN¥8.0b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 1 Fair Values set on narratives written by author

605116 Share Price Performance

CN¥19.84
-3.61 (-15.39%)
CN¥19.84
-3.61 (-15.39%)
Price CN¥19.84

605116 Community Narratives

There are no narratives available yet.

Trending Discussion

No trending discussion available.

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Excellent balance sheet with acceptable track record.

1 Risk
2 Rewards

Aurisco Pharmaceutical Co.,Ltd. Key Details

CN¥1.7b

Revenue

CN¥720.9m

Cost of Revenue

CN¥963.9m

Gross Profit

CN¥570.1m

Other Expenses

CN¥393.7m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Aug 29, 2026
0.98
57.21%
23.37%
34.8%
View Full Analysis

About 605116

Founded
1998
Employees
2026
CEO
Dingjun Chu
WebsiteView website
www.aurisco.com

Aurisco Pharmaceutical Co.,Ltd. engages in the research, development, production and sales of special complex APIs, pharmaceutical intermediates and preparations worldwide. The company offers APIs and intermediates of respiratory system, cardiovascular, anti-infection, nervous system, anti-tumor, and women's health drugs. It also provides eplerenone, an API to treat cardiovascular diseases, lowering blood pressure, and treating heart failure; futicasone propionate, used for the treatment of asthma, respiratory tract diseases, and rhinitis; Tenofovir, an anti-infection used to treat AIDS and hepatitis B; pregabalin for the treatment of anti-epileptic, analgesic, and anti-anxiety purposes, as well as for neuralgia; abiraterone acetate to treat prostate cancer; and dydrogesterone, to treat endogenous for women’s heath. Aurisco Pharmaceutical Co.,Ltd. was founded in 1998 and is headquartered in Tiantai, China.

Recent 605116 News & Updates

Recent updates

No updates